Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

300.20 -2.21 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
Netflix And Amazon Lead The Nasdaq Higher Tuesday
U.S. Indices continued higher Tuesday as the market rebounds from last week's weakness following a shift in the Fed's policy. ... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval
Here's one longtime healthcare expert's perspective. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
Expert Ratings for Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ra... 
Via Benzinga
Could Biogen's Stunning Alzheimer's Drug Victory Only Be Temporary?
In theory, yes. Realistically, probably not. 
Via The Motley Fool
3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations
Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week. 
Via The Motley Fool
Did This Company Just Win Big Because of Biogen?
Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit. 
Via The Motley Fool
Exposures Product Safety
Biogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know
One of these agreements could be more important than the other. 
Via The Motley Fool
2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen
One is Biogen's partner. The other is a potential rival. 
Via The Motley Fool
Here's Why Sage Therapeutics Tanked This Week
The neuroscience-focused biotech company didn't give investors the result they wanted. 
Via The Motley Fool
Wall Street In Fives: Must Read Lists At Midday - Friday, June 18
Get caught up quickly on the top news and calls moving stocks with these 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE: 
Via Benzinga
Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner
While Senator Joe Manchin has been vocal on his opposition to Janet Woodcock as Biden’s choice for FDA commissioner, he spelled out detailed concerns in a letter to... 
Via Benzinga
Exposures Product Safety
Is It Too Late to Buy Biogen Stock?
Probably not, but things could still get complicated. 
Via The Motley Fool
10 Biggest Price Target Changes For Friday
Piper Sandler raised Adobe Inc. (NASDAQ: ADBE) price target from $570 to $600. Adobe shares rose 3.3% to $569.50 in pre-market trading. SVB Leerink boosted Jazz... 
Via Benzinga
Why Did the FDA Approve Biogen's Alzheimer's Disease Drug After an Advisory Panel Recommended Against It?
The bottom line: The FDA can do what it wants to do. 
Via The Motley Fool
Exposures Product Safety
AMD And Nvidia Lead The Nasdaq Higher Thursday
U.S. indices had a mixed day of trading following Wednesday's Fed announcement. The Fed raised its inflation outlook for 2021 an... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059
Biogen Inc (NASDAQ: BIIB) has dosed the first patient in the TOPAZ-1 Phase 3 study evaluating BIIB059 in participants with active systemic lupus erythematosus (SLE... 
Via Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The... 
Via Benzinga
Best and Worst Russell 1000 Stocks So Far in June
Right at the midpoint of June, Biogen has been the top-performing Russell 1,000 stock month to date. 
Via Talk Markets
First Patient Set To Receive Biogen's Alzheimer's Drug: Reuters
A U.S. hospital on Wednesday will give the first infusion of Biogen Inc's (NASDAQ: BIIB) expensive, controversial Alzheimer's drug approved a week ago.... 
Via Benzinga
Cramer Shares His Thoughts On Vertex Pharma, Snap And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said it's a good opportunity to pick up some Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). The stock... 
Via Benzinga
These 2 Biotech Stocks Are Up 1,000% This Year
New approaches to treating Alzheimer's could mean even bigger gains in the future. 
Via The Motley Fool
How Has Biogen Soared 61% This Year, But Still Costs Only $1?
Biogen's newest FDA clearance sent shares soaring, but investors can still buy this stock for as little as $1. 
Via The Motley Fool
Exposures Product Safety
Tesla And Biogen Lead The SPY Lower Tuesday
U.S. indices were trading lower Tuesday as investors await an outcome from this week's Fed meeting. The 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Anavex Stock Nearly Round-Tripped Its Double-Digit Gain This Week
Researchers featured a pair of Anavex Life Sciences drugs in a paper on Alzheimer's disease this week, but AVXL stock plunged on Tuesday. 
Via Investor's Business Daily
Here's Why Sage Therapeutics Stock Is Sliding Today
Long-awaited clinical trial results weren't as successful as hoped. 
Via The Motley Fool
2 Large Cap Biotech Stocks Up More Than 25% in the Last Month
Biotech stocks are an area of the market that can deliver massive returns to investors, however, this potential reward does come with massive risk. 
Via Talk Markets
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.